c55bb20b-c929-42e2-be7f-8b1da7bee953
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.700
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.600
- ANGIOGENESIS+0.500
- COMPLEMENT+0.500
- IL6_JAK_STAT3_SIGNALING+0.500
- INFLAMMATORY_RESPONSE+0.500
- APICAL_SURFACE+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- IL2_STAT5_SIGNALING+0.400
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- ADIPOGENESIS-0.200
- DNA_REPAIR-0.200
- CHOLESTEROL_HOMEOSTASIS-0.100
- NOTCH_SIGNALING-0.100
- PEROXISOME-0.100
- UNFOLDED_PROTEIN_RESPONSE-0.100
- BILE_ACID_METABOLISM+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.917 |
| 2 | s0122206 | — | — | 0.909 |
| 3 | TCGA-GV-A3QG-01A-11R-A220-07 | — | — | 0.906 |
| 4 | TCGA-DK-A3IU-01A-11R-A20F-07 | — | — | 0.899 |
| 5 | 9f621704-2ece-4b25-be28-5fe14f71048d | — | — | 0.898 |
| 6 | MDT-AP-2869 | Med | Medulloblastoma | 0.893 |
| 7 | TCGA-44-6779-01A-11R-1858-07 | — | cohortA1 | 0.883 |
| 8 | cadbc884-10b6-41e4-8aee-dc11a1453b8c | — | — | 0.881 |
| 9 | SRR615467 | GTEX | — | 0.880 |
| 10 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.880 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.700 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.500 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.400 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |